Loading clinical trials...

COMPLETED

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

A Phase IV, Multicenter, Cross-sectional Study to Evaluate the I50L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)

NCT00135447•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out the frequency of the I50L substitution among patients experiencing treatment failure on an atazanavir-containing regimen.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Atazanavir - containing antiretroviral regimen
•Confirmed virologic failure defined as either:
•1. HIV RNA by PCR greater than or equal to 1000 copies/mL after achieving a value of \<400 copies/mL on at least 2 consecutive measurements or
•2. HIV RNA greater than or equal to 1000 copies/mL after 24 weeks of continuous therapy
•At least 18 years old

Exclusion Criteria

•Unable to give informed consent
•Prisoners or subjects involuntarily incarcerated for treatment of psychiatric or physical illness

Locations (84)

Local Institution

Phoenix, Arizona, United States

Vista Medical Partners

Beverly Hills, California, United States

AIDS Healthcare Foundation

Beverly Hills, California, United States

AltaMed Health Services Corporation

Los Angeles, California, United States

Kaiser Permanente

Los Angeles, California, United States

Synergy Hematology and Oncology Medical Associates

Los Angeles, California, United States

Orange Coast Medical Group

Newport Beach, California, United States

Alameda County Medical Center

Oakland, California, United States

East Bay AIDS Center

Oakland, California, United States

Desert Medical Group

Palm Springs, California, United States

Key Dates

Start Date

September 1, 2004

Primary Completion Date

September 1, 2009

Completion Date

September 1, 2009

Last Updated

April 14, 2011

Enrollment

5,000

ESTIMATED participants

Conditions

HIV Infections

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 14, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Comprehensive HIV and Harm Prevention Via Telehealth